WebHepcludex . bulevirtide . On 28 May 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a conditional. 2. marketing authorisation for the medicinal product Hepcludex. 3, intended for the treatment of chronic hepatitis delta virus (HDV) infection in adult patients with WebHepcludex (bulevirtide) An overview of Hepcludex and why it is authorised in the EU . What is Hepcludex and what is it used for? Hepcludex is an antiviral medicine used to …

Bulevirtide: First Approval - Springer

Web4 aug. 2024 · HEPCLUDEX ® has been approved as the first treatment option for adult patients with chronic hepatitis delta virus infection and compensated liver disease in … Web24 jun. 2024 · Hepcludex has been granted Conditional Marketing Authorization by the European Commission and PRIority MEdicines (PRIME) scheme eligibility by the … british typhoon jet

Gilead Sciences to Acquire MYR GmbH Business Wire

WebThe drug, which blocks the entry of the hepatitis B and hepatitis D virus into the liver cell, was approved by the European Commission on 31 July 2024 as a drug with the trade name Hepcludex, initially for hepatitis D. The potential uses for … WebThe following table provides supplementary information on the manufacturer and approved indication (s) for each medicine that received first-time market authorization by the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), and/or Health Canada in 2024. Web23 feb. 2024 · Hepcludex works by stopping HDV from entering and infecting liver cells (and is known as an entry inhibitor). In 2024, MYR Pharma, the German company that originally developed Hepcludex, was bought by Gilead Sciences, Inc., which is based in the United States, and which has since filed a Biologics Licensing Agreement for approval of … capital hotels ltd